中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
中联肝健康促进中心,中华医学会肝病学分会,中华医学会检验医学分会,等. 中国丙型病毒性肝炎院内筛查管理流程(试行)[J]. 临床肝胆病杂志, 2021, 37(7): 1534-1539. DOI: 10.3969/j.issn.1001-5256.2021.07.011
引用本文: 中联肝健康促进中心,中华医学会肝病学分会,中华医学会检验医学分会,等. 中国丙型病毒性肝炎院内筛查管理流程(试行)[J]. 临床肝胆病杂志, 2021, 37(7): 1534-1539. DOI: 10.3969/j.issn.1001-5256.2021.07.011
China Liver Health; Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Laboratory Medicine, Chinese Medical Association; Hospital Infection Management Committee of Chinese Hospital Association. In-hospital process for viral hepatitis C screening and management in China (Draft)[J]. J Clin Hepatol, 2021, 37(7): 1534-1539. DOI: 10.3969/j.issn.1001-5256.2021.07.011
Citation: China Liver Health; Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Laboratory Medicine, Chinese Medical Association; Hospital Infection Management Committee of Chinese Hospital Association. In-hospital process for viral hepatitis C screening and management in China (Draft)[J]. J Clin Hepatol, 2021, 37(7): 1534-1539. DOI: 10.3969/j.issn.1001-5256.2021.07.011

中国丙型病毒性肝炎院内筛查管理流程(试行)

DOI: 10.3969/j.issn.1001-5256.2021.07.011
详细信息

    作者说明: 封波,北京大学肝病研究所,北京100034;高燕,北京大学人民医院,北京100044;关秀茹,哈尔滨医科大学附属第一医院,哈尔滨150001;李明阳,中联肝健康促进中心,北京100853,均为共同第一作者
    通信作者: 魏来,weilai@mail.tsinghua.edu.cn; 徐小元,xiaoyuanxu6@163.com;李六亿,lucyliuyi@263.net;潘世扬,cxp1121@126.com

  • 中图分类号: R512.63

  • 摘要: 丙型病毒性肝炎是肝硬化、肝细胞癌的重要病因之一。我国约有1000万例慢性HCV感染者,但是,我国仍有大约70%以上的HCV感染者并没有被发现。根据世界卫生组织提出到2030年消除病毒性肝炎作为公共卫生危害的目标,以及医疗机构是目前我国发现HCV感染者和患者的主要场所,我们制定了《中国丙型病毒性肝炎院内筛查管理流程》,希望促进医疗机构管理、临床、检验、感染控制的多学科、多部门联合,加强医疗机构对检出抗-HCV阳性就诊者的咨询和转诊,促进慢性丙型肝炎患者的诊断和抗病毒治疗。

     

  • 附件4  丙型肝炎筛查、会诊和转诊流程图

    附件5  目前国内治疗慢性丙型肝炎的主要DAAs方案及其用法

    方案 规格 用法
    泛基因型
      索磷布韦/维帕他韦 索磷布韦400 mg/维帕他韦100 mg 1片,1次/d
      索磷布韦/可洛派韦 索磷布韦400 mg /可洛派韦60 mg 索磷布韦1片,1次/d; 可洛派韦1粒,1次/d
    特异基因型
      来迪派韦/索磷布韦 来迪派韦90 mg/索磷布韦400 mg 1片,1次/d
      艾尔巴韦/格拉瑞韦 艾尔巴韦50 mg/格拉瑞韦100 mg 1片,1次/d
      拉维达韦/达诺瑞韦/利托那韦/RBV** 拉维达韦200 mg/达诺瑞韦100 mg/利托那韦100 mg/RBV 拉维达韦1片,1次/d;达诺瑞韦1片,2次/d;利托那韦1片,2次/d;RBV
      磷酸依米他韦/索磷布韦 磷酸依米他韦100 mg/索磷布韦400 mg 磷酸依米他韦1粒,1次/d;索磷布韦1片,1次/d
    注:RBV,利巴韦林,体质量>75 kg,1200 mg/d;体质量≤75 kg,1000 mg/d,均分为2~3次服用。
    下载: 导出CSV
  • [1] World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection[EB/OL]. Geneva: World Health Organization, 2018. https://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2018/en/.
    [2] Chinese Society of Hepatology, Chinese Medical Association. Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C (2019 version)[J]. J Clin Hepatol, 2019, 35(12): 2670-2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008.

    中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019版)[J]. 临床肝胆病杂志, 2019, 35(12): 2670-2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008.
    [3] World Health Organization. Global health sector strategy on viral hepatitis 2016-2021[EB/OL]. Geneva: World Health Organization, 2016. https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/.
    [4] LIU L, XU H, HU Y, et al. Hepatitis C screening in hospitals: Find the missing patients[J]. Virol J, 2019, 16(1): 47. DOI: 10.1186/s12985-019-1157-1.
    [5] ORKIN C, LEACH E, FLANAGAN S, et al. High prevalence of hepatitis C (HCV) in the emergency department (ED) of a London hospital: Should we be screening for HCV in ED attendees?[J]. Epidemiol Infect, 2015, 143(13): 2837-2840. DOI: 10.1017/S0950268815000199.
    [6] OLAFSSON S, TYRFINGSSON T, RUNARSDOTTIR V, et al. Treatment as prevention for hepatitis C (TraP Hep C)- a nationwide elimination programme in Iceland using direct-acting agents[J]. J Intern Med, 2018, 283(5): 500-507. DOI: 10.1111/joim.12740.
    [7] CHEN YX, WU C. Establishment and implementation of hepatitis C screening and referral channels in the hospitals[J]. Chin J Hepatol, 2020, 28(10): 820-823. DOI: 10.3760/cma.j.cn501113-20200925-00531.

    陈雨欣, 吴超. 医院内丙型肝炎筛查和转诊路径的建立与实施[J]. 中华肝脏病杂志, 2020, 28(10): 820-823. DOI: 10.3760/cma.j.cn501113-20200925-00531.
    [8] FENG B, ZHANG J, WEI L. Inadequate awareness of hepatitis C among nonspecialist physicians in China[J]. Adv Med Educ Pract, 2011, 2: 209-214. DOI: 10.2147/AMEP.S23887.
    [9] GHANY MG, MORGAN TR, AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for testing, managing, and treating hepatitis C virus infection[J]. Hepatology, 2020, 71(2): 686-721. DOI: 10.1002/hep.31060.
    [10] National Health and Family Planning Commission, The People's Republic of China. Screening and management of hepatitis C[J]. Infect Dis Info, 2015, 28(1): 1-2, 22. https://www.cnki.com.cn/Article/CJFDTOTAL-CRBX201501001.htm

    中华人民共和国国家卫生和计划生育委员会. 丙型病毒性肝炎筛查及管理[J]. 传染病信息, 2015, 28(1): 1-2, 22. https://www.cnki.com.cn/Article/CJFDTOTAL-CRBX201501001.htm
  • 加载中
图(1) / 表(1)
计量
  • 文章访问数:  133
  • HTML全文浏览量:  58
  • PDF下载量:  58
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-06-17
  • 修回日期:  2021-06-17
  • 刊出日期:  2021-07-19
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回